Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sharon Farber

Neurology Chattanooga, TN Medical Doctor

NPI 1083642474 CMS profile 185372

721 Glenwood Dr 467W, Chattanooga, TN 37404

Open in the dashboard

General payments

$14,925

860 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sharon Farber of Chattanooga, TN is reported in the CMS Open Payments database as having received $14,925 across 860 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $154 7
2024 General $580 36
2023 General $2,866 169
2022 General $3,280 192
2021 General $3,298 206
2020 General $1,655 97
2019 General $3,093 153

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sharon Farber
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Sharon Farber were reported at $154. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Sharon Farber Neurology median Middle half National median
2019 $3,093 $474 $118–$2,177 $163
2020 $1,655 $367 $82–$2,309 $114
2021 $3,298 $438 $104–$2,547 $132
2022 $3,280 $442 $103–$2,388 $149
2023 $2,866 $464 $119–$2,312 $160
2024 $580 $468 $119–$2,323 $164
2025 $154 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,620 139 payments
  2. Biogen, Inc. $1,185 61 payments
  3. UCB, Inc. $890 30 payments
  4. Allergan Inc. $749 53 payments
  5. Amgen Inc. $638 28 payments
  6. Biohaven Pharmaceuticals, Inc. $618 44 payments
  7. EMD Serono, Inc. $584 35 payments
  8. Novartis Pharmaceuticals Corporation $574 31 payments
  9. Genzyme Corporation $501 18 payments
  10. ACADIA Pharmaceuticals Inc $473 30 payments
  11. Other $7,092 391 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,568 846 payments
  2. Consulting Fee $150 1 payment
  3. Education $135 9 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $72 4 payments
Products named General payments · program years 2019–2025
  1. NURTEC ODT $970 68 payments
  2. Briviact $759 25 payments
  3. BOTOX $719 45 payments
  4. AIMOVIG $703 34 payments
  5. TYSABRI $664 30 payments
  6. UBRELVY $523 58 payments
  7. QULIPTA $497 45 payments
  8. ZEPOSIA $430 34 payments
  9. INGREZZA $369 19 payments
  10. VALTOCO $362 16 payments
  11. Other $9,303 517 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

896

Median for Neurology: 833

Drug cost

$233,451

Median for Neurology: $202,670

Branded share of claims

13.7%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vigabatrin Generic 11 $192,564
Dilantin Phenytoin Sodium Extended Brand 40 $7,247
Levetiracetam Generic 243 $7,163
Lacosamide Generic 11 $5,073
Lamotrigine Generic 143 $4,034
Divalproex Sodium Generic 76 $3,443
Levocarnitine Generic 38 $3,284
Carbamazepine Generic 48 $2,054
Zonisamide Generic 43 $1,734
Carbamazepine Er Carbamazepine Brand 25 $1,642

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$11,320

Medicare's payments for the services billed

Medicare patients

90

Average age 75

Services billed

159

48 women, 42 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Ischemic heart disease 52%
Diabetes 51%
Chronic kidney disease 47%
Depression 44%
Alzheimer's or dementia 40%
Heart failure 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $67
$67 — —
Hizentra
  • CSL Behring $63
$63 — —
UBRELVY
  • AbbVie, Inc. $56
$56 — —
QULIPTA
  • AbbVie, Inc. $52
$52 — —
Gocovri
  • US WorldMeds, LLC $42
$42 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

860 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record